 BOCA RATON, Fla., July 22, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. NASDAQ: AZRX, AzurRx or the Company, a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal GI diseases, announced today that it has entered into an underwriting agreement with H.C. Wainwright Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 5,454,546 shares of common stock of the Company, at a price to the public of 0.55 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about July 27, 2021, subject to satisfaction of customary closing conditions. 